News & Events

  • December 12, 2018

    Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous...

    December 4, 2018

    Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    November 20, 2018

    Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous...

    November 14, 2018

    Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    November 12, 2018

    Nemaura Medical to Present at the Stifel 2018 Healthcare Conference

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    November 8, 2018

    Nemaura Medical Inc. Reports Second Quarter 2018 Financial Results

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    November 7, 2018

    Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    October 22, 2018

    Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments

    LOUGHBOROUGH, England – Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    September 25, 2018

    Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    September 18, 2018

    Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous...